CO2024011882A2 - Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad - Google Patents
Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidadInfo
- Publication number
- CO2024011882A2 CO2024011882A2 CONC2024/0011882A CO2024011882A CO2024011882A2 CO 2024011882 A2 CO2024011882 A2 CO 2024011882A2 CO 2024011882 A CO2024011882 A CO 2024011882A CO 2024011882 A2 CO2024011882 A2 CO 2024011882A2
- Authority
- CO
- Colombia
- Prior art keywords
- melanocortin
- obesity
- rare genetic
- treat
- prevent
- Prior art date
Links
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 208000037340 Rare genetic disease Diseases 0.000 title abstract 3
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 abstract 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 abstract 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220016377 | 2022-02-08 | ||
| PCT/KR2023/001712 WO2023153762A1 (ko) | 2022-02-08 | 2023-02-07 | 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024011882A2 true CO2024011882A2 (es) | 2025-01-23 |
Family
ID=87564659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0011882A CO2024011882A2 (es) | 2022-02-08 | 2024-08-30 | Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250134898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4461297A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505229A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230120106A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300835A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128463A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023218785A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248118A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002389A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024011882A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009854A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI838114B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023153762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202315A1 (en) * | 2020-12-22 | 2022-06-30 | Hee Dong Park | Use as selective agonist of malanocortin-4 receptor |
| KR20250046623A (ko) * | 2023-09-27 | 2025-04-03 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| US12516047B2 (en) * | 2019-11-07 | 2026-01-06 | Lg Chem, Ltd. | Melanocortin-4 receptor agonists |
| CN116507615A (zh) * | 2020-10-29 | 2023-07-28 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的晶型i及其制备方法 |
| TWI804170B (zh) * | 2021-01-21 | 2023-06-01 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑的用途 |
| TWI826938B (zh) * | 2021-02-26 | 2023-12-21 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑 |
| TWI861780B (zh) * | 2022-03-28 | 2024-11-11 | 南韓商Lg化學股份有限公司 | 預防或治療肥胖的聯合療法 |
-
2023
- 2023-02-06 TW TW112104117A patent/TWI838114B/zh active
- 2023-02-07 US US18/837,125 patent/US20250134898A1/en active Pending
- 2023-02-07 EP EP23753110.8A patent/EP4461297A4/en active Pending
- 2023-02-07 CN CN202380032193.6A patent/CN119300835A/zh active Pending
- 2023-02-07 CA CA3248118A patent/CA3248118A1/en active Pending
- 2023-02-07 JP JP2024547302A patent/JP2025505229A/ja active Pending
- 2023-02-07 KR KR1020230016160A patent/KR20230120106A/ko not_active Ceased
- 2023-02-07 AR ARP230100283A patent/AR128463A1/es unknown
- 2023-02-07 AU AU2023218785A patent/AU2023218785A1/en active Pending
- 2023-02-07 WO PCT/KR2023/001712 patent/WO2023153762A1/ko not_active Ceased
-
2024
- 2024-08-08 CL CL2024002389A patent/CL2024002389A1/es unknown
- 2024-08-12 MX MX2024009854A patent/MX2024009854A/es unknown
- 2024-08-30 CO CONC2024/0011882A patent/CO2024011882A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505229A (ja) | 2025-02-21 |
| AU2023218785A1 (en) | 2024-08-22 |
| CA3248118A1 (en) | 2025-01-24 |
| WO2023153762A1 (ko) | 2023-08-17 |
| EP4461297A4 (en) | 2025-04-09 |
| CL2024002389A1 (es) | 2025-01-31 |
| TW202339761A (zh) | 2023-10-16 |
| CN119300835A (zh) | 2025-01-10 |
| AR128463A1 (es) | 2024-05-08 |
| TWI838114B (zh) | 2024-04-01 |
| EP4461297A1 (en) | 2024-11-13 |
| US20250134898A1 (en) | 2025-05-01 |
| KR20230120106A (ko) | 2023-08-16 |
| MX2024009854A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009854A (es) | Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genetica rara de la obesidad | |
| Yang et al. | MiR-155 aggravated septic liver injury by oxidative stress-mediated ER stress and mitochondrial dysfunction via targeting Nrf-2 | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| JOP20220056A1 (ar) | مركبات rip1 تثبيطية وطرق عملها واستخدامها | |
| AU2025283528A1 (en) | Methods of treating WHSC1-overexpressing cancers by inhibiting SETD2 | |
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| GT200500158A (es) | Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa | |
| ECSP22092977A (es) | Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita | |
| MXPA04002537A (es) | Alquinos como inhibidores de metaloproteinasa de matriz. | |
| CU20080027A7 (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
| SV2007002146A (es) | Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727 | |
| MX2023008098A (es) | Uso de agonista del receptor de melanocortina-4. | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| BR0208957A (pt) | Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc | |
| NZ598778A (en) | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions | |
| CL2008003798A1 (es) | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. | |
| CL2008001238A1 (es) | Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi | |
| ECSP088387A (es) | Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms | |
| CL2012001349A1 (es) | Uso de una composicion farmaceutica que comprende telmisartan para el tratamiento de hipertension sistemica en gatos ( div. sol. 2897-07). | |
| CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| CL2011000165A1 (es) | Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| MX2024008450A (es) | Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones | |
| CR10111A (es) | Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido |